OM protein - protein search, using sw model

Run on: November 27, 2002, 05:38:32 ; Search time 8.28185 Seconds
(without alignments)
241.342 Million cell updates/sec

Title: US-09-893-615-2
Perfect score: 91
Sequence: 1 WHWRHRIPLQLAAGR 15

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 908470 seqs, 133250620 residues

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_101002:*
1: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1980.DAT:*
2: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1981.DAT:*
3: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1982.DAT:*
4: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1983.DAT:*
5: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1984.DAT:*
6: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1985.DAT:*
7: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1986.DAT:*
8: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1987.DAT:*
9: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1988.DAT:*
10: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1989.DAT:*
11: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1990.DAT:*
12: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1991.DAT:*
13: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1992.DAT:*
14: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1993.DAT:*
15: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1994.DAT:*
16: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1995.DAT:*
17: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1996.DAT:*
18: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1997.DAT:*
19: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1998.DAT:*
20: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1999.DAT:*
21: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2000.DAT:*
22: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2001.DAT:*
23: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	91	100.0	15	17	AAW12276	Synthetic library
2	91	100.0	15	19	AAW71334	A glycolipid sugar
3	91	100.0	15	20	AAW94702	Lipoteichoic acid
4	91	100.0	15	21	AAB17987	Beta-2GPI Ab bindi
5	91	100.0	15	23	ABB73358	Exemplary pharmaco
6	91	100.0	19	20	AAW94729	Sequence 15mer 2nd
7	91	100.0	19	20	AAW94710	Sequence 15mer2-8/
8	91	100.0	19	20	AAW94721	Sequence 15mer2-19
9	91	100.0	19	20	AAW94705	Sequence 15mer2-1/
10	91	100.0	19	20	AAW94709	Sequence 15mer2-7/
11	91	100.0	37	17	AAW12287	Synthetic template
12	80	87.9	19	20	AAW94708	Sequence 15mer2-5/
13	69	75.8	15	17	AAW12277	Synthetic library
14	56	61.5	11	17	AAW03372	Peptide #6 which b
15	56	61.5	15	17	AAW03374	Peptide #8 which b
16	51	56.0	159	22	ABG15894	Novel human diagno
17	50	54.9	11	17	AAW03373	Peptide #7 which b
18	50	54.9	15	17	AAW03375	Peptide #9 which b
19	50	54.9	139	22	ABB27778	Human peptide #429
20	50	54.9	139	22	ABB32949	Peptide #455 encod
21	50	54.9	139	22	ABB18423	Protein #422 encod
22	50	54.9	139	22	AAM53750	Human brain expres
23	50	54.9	139	22	AAM66133	Human bone marrow
24	50	54.9	139	22	AAM14004	Peptide #438 encod
25	50	54.9	139	22	AAM26410	Peptide #447 encod
26	50	54.9	139	22	AAM01745	Peptide #427 encod
27	50	54.9	139	23	ABG35783	Human peptide enco
28	49	53.8	157	22	AAG81442	Human AFP protein
29	49	53.8	157	23	ABB77573	Human mast cell re
30	46.5	51.1	74	21	AAG54412	Zea mays protein f
31	46	50.5	11	17	AAW03370	Peptide #4 which b
32	46	50.5	15	17	AAW03371	Peptide #5 which b
33	46	50.5	71	22	AAM06299	Human foetal prote
34	46	50.5	536	21	AAY84592	Amino acid sequenn
35	44.5	48.9	285	23	AAM51648	Rat GPCR polypepti
36	44.5	48.9	298	15	AAR48755	Human thoracic aor
37	44.5	48.9	298	17	AAW02727	Human thoracic aor
38	44.5	48.9	343	23	ABB08348	RTA-like G protein
39	44	48.4	305	22	ABG09714	Novel human diagno
40	43.5	47.8	74	23	ABP02393	Human ORFX protein
41	43.5	47.8	385	22	AAM93386	Human polypeptide,
42	43	47.3	51	22	AAM56677	Human brain expres
43	43	47.3	51	22	AAM29377	Peptide #3414 enco
44	43	47.3	117	22	AAU64601	Propionibacterium
45	43	47.3	367	22	ABB71448	Drosophila melanog

ALIGNMENTS

RESULT 1
AAW12276
ID AAW12276 standard; peptide; 15 AA.
XX
AC AAW12276;
XX
DT 15-APR-1997 (first entry)
XX
DE Synthetic library peptide #1 which binds anti-T. gondii P30 antibody.
XX
KW Toxoplasma gondii; surface protein; antibody; screening; peptide library;
KW diagnostic assay; immunisation; phage; fusion protein; envelop.
XX
OS Synthetic.
XX
PN EP724016-A1.
XX
PD 31-JUL-1996.
XX
PF 29-JAN-1996; 96EP-0420030.
XX
PR 30-JAN-1995; 95FR-0001297.
XX
PA (JOLI/) JOLIVET-REYNAUD C.
PA (INMR) BIO MERIEUX.
XX
PI Jolivet-Reynaud C;
XX
DR WPI; 1996-343531/35.
XX
PT New polypeptide reactive with anti-P30 antibodies against Toxoplasma
PT gondii - useful for diagnosis or immunisation, also new nucleic
PT acid, vectors and transformed cells

XX
PS Example 2; Page 7; 33pp; French.
XX
CC The invention relates to novel peptides which bind to antibodies which
CC recognise the Toxoplasma gondii P30 envelop protein. A peptide library
CC was generated to express pentadecapeptides on the surface of a
CC filamentous phage as a fusion protein with the PIII protein. The library
CC was screened with immobilised anti-T. gondii P30 protein antibody 1E1E7.
CC Phages which bind this antibody were recovered and amplified by one
CC round of infection in E. coli. The resultant phages were rescreened with
CC the immobilised antibody and the second round screen isolated 58
CC bacterial colonies infected with phage. Of the 58 colonies, phage DNA
CC from 30 colonies was isolated and sequenced to determine the sequence of
CC the pentadecapeptide encoded. The peptide sequences AAW12276-86 were
CC identified. Of the 30 colonies studied, this peptide sequence was
CC encoded 11 times. A template peptide sequence (AAW12287) corresponding
CC to the sequence across the phage PIII sequence and putative
CC pentadecapeptide was used to generate a series of overlapping
CC pentadecapeptides. These peptides were used to determine the best
CC peptide sequence which binds the 1E1E7 antibody. Peptides AAW03367-75
CC were isolated. The new peptides can then be used in diagnostic assays to
CC detect T. gondii antibodies in a sample or to purify anti-P30 antibodies
CC or for active immunisation against T. gondii.
XX
SQ Sequence 15 AA;

Query Match 100.0%; Score 91; DB 17; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e-08;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 WHWRHRIPLQLAAGR 15
||||||||||||||||
Db 1 WHWRHRIPLQLAAGR 15

RESULT 2
AAW71334
ID AAW71334 standard; peptide; 15 AA.
XX
AC AAW71334;
XX
DT 25-NOV-1998 (first entry)
XX
DE A glycolipid sugar chain peptide.
XX
KW Glycolipid sugar chain; inhibit; adhesion; metastasis; cancer cell.
XX
OS Synthetic.
XX
PN JP10237099-A.
XX
PD 08-SEP-1998.
XX
PF 26-FEB-1997; 97JP-0042311.
XX
PR 26-FEB-1997; 97JP-0042311.
XX
PA (IMMO) IMMUNO JAPAN INC.
XX
DR WPI; 1998-537488/46.
XX
PT New peptide which reacts specifically with antibody against
PT glyco-lipid sugar chains - useful for inhibition of cancer
PT metastasis
XX
PS Claim 8; Page 3; 7pp; Japanese.
XX
CC AAW71332-36 represent glycolipid sugar chain replica peptides. They
CC react specifically with an antibody against glycolipid sugar chains
CC and inhibit adhesion and metastasis of cancer cells to a target cell.
CC The peptides can be used to prevent cancer metastasis.
XX
SQ Sequence 15 AA;

Query Match 100.0%; Score 91; DB 19; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e-08;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 WHWRHRIPLQLAAGR 15
||||||||||||||||
Db 1 WHWRHRIPLQLAAGR 15

RESULT 3
AAW94702
ID AAW94702 standard; peptide; 15 AA.
XX
AC AAW94702;
XX
DT 22-APR-1999 (first entry)
XX
DE Lipoteichoic acid epitope peptide mimic for Mab 96-110.
XX
KW Monoclonal antibody; MAb; lipoteichoic acid; gram positive; bacteria;
KW immunoglobulin; phagocytosis; infection; epitope; peptide mimic;
KW Mab 96-110.
XX
OS Staphylococcus sp.
XX
PN WO9857994-A2.
XX
PD 23-DEC-1998.
XX
PF 16-JUN-1998; 98WO-US12402.
XX
PR 16-JUN-1997; 97US-0049871.
XX
PA (JACK-) JACKSON FOUND ADVANCEMENT MILITARY MED.
XX
PI Fischer GW, Schuman RF, Stinson JL, Wong H;
XX
DR WPI; 1999-095329/08.
XX
PT New antibodies to lipoteichoic acid of gram positive bacteria - used
PT to develop products for the diagnosis, prevention and treatment of
PT infections caused by gram positive bacteria
XX
PS Claim 16; Page 120; 150pp; English.
XX
CC The invention relates to a monoclonal antibody (MAb) to lipoteichoic acid
CC of gram positive bacteria, where the MAb is a chimeric immunoglobulin
CC comprising at least part of a human immunoglobulin constant region and
CC at least part of a non-human immunoglobulin variable region having
CC specificity to lipoteichoic acid of gram positive bacteria. The
CC antibodies bind to whole bacteria and enhance phagocytosis and killing of
CC the bacteria and enhance protection from lethal infection. The antibodies
CC or peptides (encoded by a DNA of the variable region of anti-lipoteichoic
CC acid antibody or characterised by amino acids corresponding to one or
CC more of the complementarity determining regions (CDRs) of the variable
CC region of the antibody) can be used for treating or preventing infections
CC caused by gram positive bacteria. They can also be used for the diagnosis
CC of gram positive bacterial infections. The present sequence represents a
CC specifically claimed lipoteichoic acid epitope peptide mimic that can be
CC bound by the antibody of the invention (Mab 96-110).
XX
SQ Sequence 15 AA;

Query Match 100.0%; Score 91; DB 20; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e-08;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 WHWRHRIPLQLAAGR 15
||||||||||||||||
Db 1 WHWRHRIPLQLAAGR 15

RESULT 4
AAB17987
ID AAB17987 standard; Peptide; 15 AA.
XX
AC AAB17987;
XX
DT 31-OCT-2000 (first entry)
XX
DE Beta-2GPI Ab binding peptide sequence SEQ ID NO:1099.
XX
KW Modified peptide; therapeutic agent; fusion; Fc domain; cancer;
KW autoimmune disease; cytostatic; antiasthmatic; thrombolytic; VEGF;
KW immunosuppressive; EPO; TPO; CTLA4; mimetic; IL-1; TNF; antagonist;
KW MMP; inhibitor; erythropoietin; thrombopoietin; interleukin 1;
KW cytotoxic T cell lymphocyte antigen 4; tumour necrosis factor;
KW vascular endothelial growth factor; matrix metalloproteinase;
KW asthma; thrombosis; pharmaceutical.
XX
OS Synthetic.
XX
PN WO200024782-A2.
XX
PD 04-MAY-2000.
XX
PF 25-OCT-1999; 99WO-US25044.
XX
PR 23-OCT-1998; 98US-0105371.
PR 22-OCT-1999; 99US-0428082.
XX
PA (AMGE-) AMGEN INC.
XX
PI Feige U, Liu C, Cheetham J, Boone TC;
XX
DR WPI; 2000-350702/30.
XX
PT Novel composition of matter comprising an Fc domain and
PT pharmacologically active peptides, useful for treating cancer and
PT autoimmune diseases -
XX
PS Claim 39; Page 598; 608pp; English.
XX
CC The present invention describes composition of matter (I) comprising an
CC Fc domain, pharmacologically active peptides, and linkers. Where (I) is:
CC (X1)a-F1-(X2)b, where: F1 = an Fc domain; X1 and X2 = are each
CC independently selected from -(L1)c-P1, -(L1)c-P1-(L2)d-P2,
CC -(L1)c-P1-(L2)d-P2-(L3)e-P^3, or -(L1)c-P1-(L2)d-P2-(L3)e-P3-(L4)f-P4
CC where P1, P2, P3, and P4 = are each independently sequences of
CC pharmacologically active peptides; L1, L2, L3, and L4 = are each
CC independently linkers; and a, b, c, d, e, and f = are each independently
CC 0 or 1, provided that at least 1 of a and b is 1. The composition can
CC have cytostatic, antiasthmatic, thrombolytic and immunosuppressive
CC activities. DNAs, vectors and host cells from the present invention can
CC be used for producing pharmaceutical compositions. The compositions are
CC useful for treating cancer, asthma, thrombosis, or autoimmune diseases.
CC The use of an Fc domain (rather than a Fab domain) can provide a longer
CC half-life or incorporate functions such as Fc receptor binding, protein
CC A binding, complement fixation, and possibly placental transfer. AAA69443
CC to AAA69526 and AAB16955 to AAB18003 represent nucleotide and amino acid
CC sequences used in the exemplification of the present invention.
XX
SQ Sequence 15 AA;

Query Match 100.0%; Score 91; DB 21; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e-08;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 WHWRHRIPLQLAAGR 15
||||||||||||||||
Db 1 WHWRHRIPLQLAAGR 15

RESULT 5
ABB73358
ID ABB73358 standard; Peptide; 15 AA.
XX
AC ABB73358;
XX
DT 05-APR-2002 (first entry)
XX
DE Exemplary pharmacologically active peptide SE
XX
KW Modified peptide; mimetic; Fc domain; fusion; I
KW EPO; erythropoietin; TPO; tumour necrosis factor
KW TNF-alpha inhibitor; interleukin 1 antagonist; IL
KW TPO mimetic peptide; EPO mimetic peptide; EMP; VEG
KW MMP inhibitor; antiinflammatory; antitumour; immunosup
KW cytostatic; antirheumatic; antiarthritic; antidiabetic;
KW antianaemic; anorectic; antiinfertility; haemostatic; de
KW neuroprotective; inflammatory disease; autoimmune disease
KW cancer; rheumatoid arthritis; diabetic retinopathy; infe
KW sleep disorder; neurological degenerative disease; anaemia
KW thrombocytopaenia; metastatic tumour; systemic lupus eryth
KW Fanconi's syndrome.
XX
OS Synthetic.
XX
PN WO200183525-A2.
XX
PD 08-NOV-2001.
XX
PF 02-MAY-2001; 2001WO-US14310.
XX
PR 03-MAY-2000; 2000US-0563286.
XX
PA (AMGE-) AMGEN INC.
XX
PI Feige U, Liu C, Cheetham JC, Boone TC, Gudas JM;
XX
DR WPI; 2002-130313/17.
XX
PT Novel vehicle-peptide molecule or its multimers useful for treating
PT inflammatory and autoimmune diseases, cancer, rheumatoid arthritis,
PT diabetic retinopathy, obesity, sleep disorders and infertility -
XX
PS Claim 39; Page 62; 176pp; English.
XX
CC The present invention describes a vehicle-peptide molecule (I) or its
CC multimers. (I) can have antiinflammatory, antitumour, immunosuppressive,
CC cytostatic, antirheumatic, antiarthritic, antidiabetic, ophthalmological,
CC antianaemic, anorectic, antiinfertility, haemostatic, dermatological and
CC neuroprotective activities. (I) can be used as a therapeutic or
CC prophylactic agent as well as for screening purposes. (I) is useful for
CC diagnosing diseases characterised by dysfunction of their associated
CC protein of interest, for identifying normal or abnormal proteins of
CC interest, as a part of diagnostic kit to detect the presence of their
CC proteins of interest in a biological sample. Additionally, (I) is useful
CC for treating inflammatory and autoimmune diseases, tumour growth, cancer,
CC rheumatoid arthritis, diabetic retinopathy, obesity, sleep disorders,
CC infertility, and neurological degenerative diseases. (I), comprising
CC EPO-mimetic compounds are useful for treating disorders characterised by
CC low red blood cell levels such as anaemia. The TPO-mimetic comprising
CC compounds are useful for treating conditions that involve an existing
CC megakaryocyte/platelet deficiency or an expected megakaryocyte/platelet
CC deficiency, such as thrombocytopaenia, aplastic anaemia, metastatic
CC tumour which result in thrombocytopaenia, systemic lupus erythematosus,
CC and Fanconi's syndrome. ABB72403 to ABB73426 and ABL35695 to ABL35777
CC represent amino acid and nucleic acid sequences used in the
CC exemplification of the present invention.
XX
SQ Sequence 15 AA;

Query Match 100.0%; Score 91; DB 23; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e-08;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 WHWRHRIPLQLAAGR 15